DuramycinDuramycin
MedChemExpress (MCE)
HY-106302
1391-36-2
Moli1901
Lancovutide
99.46%
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Room temperature in continental US
may vary elsewhere.
Duramycin (Moli1901) is a lantibiotic derived from Streptomyces cinnamoneuma. Duramycin also is a antimicrobial peptide. Duramycin can be used for the research of cystic fibrosis (CF).
Evaluation of [68Ga]NODAGA-Duramycin as a positron emission tomography (PET) tracer of cell death for whole-body detection of chemotherapy-induced organ toxicity. Organ uptake is analyzed in untreated and doxorubicin, busulfan, and cisplatin-treated mice 2 h after intravenous injection of [68Ga]NODAGA-Duramycin. [68Ga]NODAGA-Duramycin PET/CT is successfully applied to non-invasively detect chemotherapy-induced organ toxicity with high sensitivity in mice[3].
Cys-Lys-Gln-Cys-Cys-Ala-Phe-Gly-Pro-Phe-{Abu}-Phe-Val-Cys-Asp-Gly-Asn-{Abu}-Lys-NH2 (Disulfide bridge: Cys1-Abu18, Cys4-Cys14, Cys5-Abu11)
| | | |
| | | | | |
[1]. Oliynyk I, et al. Effect of duramycin on chloride transport and intracellular calcium concentration in cystic fibrosis and non-cystic fibrosis epithelia. APMIS. 2010 Dec
118(12):982-90. [Content Brief]
[2]. Huo L, et al. Insights into the Biosynthesis of Duramycin. Appl Environ Microbiol. 2017 Jan 17
83(3). pii: e02698-16. [Content Brief]